We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Survival Rates Following Hepatoma Resection Continues to Improve

By HospiMedica International staff writers
Posted on 16 Mar 2011
Survival after resection of hepatocellular carcinoma (HCC) has improved significantly over the past 20 years, even in patients with advanced disease, according to a new report.

Researchers at Queen Mary Hospital (Hong Kong, China) and the University of Hong Kong (HKU; China; www.hku.hk) investigated the trend of the posthepatectomy survival outcomes of HCC patients by analysis of a prospective cohort of 1,198 patients between 1989 and 2008. More...
The patients were categorized into two 10-year periods: period 1, before 1999 (totaling 390 patients), and period 2, after 1999 (totaling 808 patients). Patients in group 2 were managed according to a modified protocol and technique established in previous years.

The results showed that the patients in group 2 were older and had a higher incidence of comorbid illness and cirrhosis. Despite this, they had a lower hospital mortality rate, longer 5-year overall survival, and higher disease-free survival rates. An improvement in the overall survival rate was observed in patients with cirrhosis, those undergoing major hepatectomy, and those with tumors of tumor-node-metastasis stages II, IIIA, and IVA. A significant increase in the survival rates was also seen in patients whose tumors were considered transplantable. In all, multivariate analysis showed a significantly more favorable patient survival for hepatectomy in period 2. The study was published early online on February 17, 2011, in the Annals of Surgery.

"Further improvement of results depends on technical refinement to reduce blood loss to the minimum, avoid blood transfusion, preserve liver remnant function, secure tumor-free resection margins, and meticulous perioperative care to reduce complications,” said lead author Prof. Sheung Tat Fan, MD, and colleagues of the Laboratory for Liver Research at HKU and Queen Mary Hospital. "Life-long surveillance for recurrence and prompt treatment are mandatory, but development of more effective local ablation methods are needed to lengthen postrecurrence survival.”


Related Links:

Queen Mary Hospital

University of Hong Kong

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Digital Color Doppler Ultrasound System
MS22Plus
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.